


Supplementary Table 1 Univariate analysis in the unmatched group

Variable	Disease-free survival			Distant metastasis-free survival			Loco-regional relapse-free survival			Overall survival		
	HR	CI (%)	<i>P</i>	HR	CI (%)	<i>P</i>	HR	CI (%)	<i>P</i>	HR	CI (%)	<i>P</i>
Sex												
Female	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
Male	1.13	0.74–1.71	0.573	1.77	0.90–3.49	0.098	1.87	0.92–3.81	0.084	1.08	0.63–1.87	0.777
Age												
≤45	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
>45	1.02	0.72–1.45	0.923	0.75	0.45–1.25	0.271	1.37	0.82–2.30	0.227	2.22	1.36–3.61	0.001
KPS												
70–80	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
90–100	0.41	0.15–1.09	0.073	0.26	0.08–0.84	0.024	0.74	0.10–5.37	0.769	0.29	0.09–0.91	0.033
T classification												
T1–2	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
T3	0.91	0.53–1.56	0.727	0.58	0.29–1.19	0.137	1.07	0.48–2.38	0.873	0.62	0.33–1.19	0.149
T4	1.47	0.80–2.71	0.214	1.54	0.71–3.30	0.273	1.31	0.51–3.38	0.578	1.34	0.65–2.76	0.427
N classification												
N0–1	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
N2–3	1.24	0.87–1.76	0.238	1.97	1.18–3.26	0.009	1.29	0.77–2.15	0.340	1.68	1.05–2.67	0.030
Clinical stage												
III	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
IV	1.61	1.10–2.37	0.015	2.81	1.69–4.67	<0.001	1.00	0.53–1.89	0.999	2.25	1.39–3.64	0.001
Treatment												
Triweekly	Ref.	Ref.		Ref.	Ref.		Ref.	Ref.		Ref.	Ref.	
Weekly	0.68	0.43–1.06	0.085	0.44	0.21–0.92	0.029	0.99	0.55–1.78	0.962	1.04	0.61–1.75	0.892



Supplementary Figure 1: Compliance of concurrent cisplatin chemotherapy in the well-balanced cohort. (A) Weekly regimen. (B) Triweekly regimen.